Full-Time

Director – Health Systems

Karius

Karius

201-500 employees

Non-invasive liquid biopsy for infectious pathogens

Compensation Overview

$178.3k - $267.4k/yr

Remote in USA

Remote

Bachelor's, MBA

Category
Medical, Clinical & Veterinary (1)
Required Skills
Sales
Forecasting
Salesforce
Data Analysis

Get referred to Karius

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Business, Healthcare Administration, Life Sciences, or a related field required.
  • Advanced degree such as MBA, MPH, MHA, or equivalent strongly preferred.
  • 8-10+years of progressive experience in healthcare partnerships, sales, or business development, with a strong focus on strategic health system or IDN accounts.
  • Demonstrated success building and managing high-value partnerships in the healthcare or biotech industry.
  • Proven experience negotiating and managing complex health system contracts in collaboration with Legal and other internal partners.
  • Experience leading Business and Utilization Reviews that clearly communicate clinical, operational, and financial return on investment to health system executives.
  • Track record of identifying and executing expansion opportunities within health systems, including additional sites, service lines, and affiliated networks.
  • Experience fostering strategic partnerships with external organizations such as consortia, alliances, or integrated health networks.
  • Demonstrated ability to manage complex sales cycles and multi stakeholder decision processes inside hospitals and health systems.
  • Exceptional communication, negotiation, and presentation skills, including confidence presenting to executive audiences and at national conferences.
  • Proficiency with CRM tools such as Salesforce and a data driven approach to forecasting, pipeline reviews, and account planning.
  • Strong knowledge of the biotech or medical diagnostics industry and familiarity with hospital operations, decision making processes, and value analysis pathways.
  • Thinks strategically and can design and execute initiatives that align near term priorities with long term business objectives.
  • Builds strong trust and credibility with executive decision makers, physicians, and operational leaders, acting as a strategic partner to health system stakeholders.
  • Communicates complex clinical, operational, and financial concepts clearly and persuasively, tailoring messages to executives, clinicians, and internal teams.
  • Uses data, market trends, and customer feedback to inform decisions, refine partnership strategies, and prioritize opportunities.
  • Thrives in a fast paced, evolving environment, adapting approach as market conditions, customer needs, and organizational priorities change.
  • Brings a resourceful, solution focused mindset and consistently overcomes obstacles to move initiatives forward and deliver results.
  • Demonstrates a deep commitment to understanding customer needs and delivering differentiated value through innovative solutions and high quality service.
  • Operates with professionalism, sound judgment, and high ethical standards, taking clear ownership for outcomes and follow through.
Responsibilities
  • Consistently exceed performance expectations, driving measurable growth in test volume and account value across the assigned health system portfolio.
  • Build trusted, long-term strategic relationships with executive leaders, administrators, and clinical stakeholders to drive enterprise-level integration of the Karius Test.
  • Lead Business and Utilization Reviews with system executives, demonstrating clinical, operational, and financial ROI.
  • Identify and prioritize expansion opportunities within assigned health systems, including additional sites, service lines, and affiliated networks.
  • Establish Centers of Excellence and cultivate Clinical Champions to accelerate adoption and advocacy.
  • Identify and pursue outpatient and private payor opportunities within assigned health systems where appropriate, expanding Karius’s footprint beyond inpatient use cases.
  • Secure and manage enterprise agreements, contracts, and renewals in collaboration with Legal, ensuring alignment with company goals and compliance requirements.
  • Support forecasting, pipeline reviews, and account planning with system-level insights.
  • Serve as the primary point of coordination across Sales, Medical Affairs, Marketing, Legal, and Customer Success for assigned accounts, ensuring coordinated execution, test volume growth, new account generation, and consistent system-level messaging.
  • Partner with field leaders to align execution with strategic account priorities.
  • Provide insights from health system engagements to refine commercial strategy, product positioning, and evidence generation.
  • Promote partnership successes and expand advocacy across Health Systems and IDNs to drive broader adoption.
  • Ensure account activities and strategies are documented in Salesforce and tracked against commercial KPIs.
  • Maintain accountability for execution while ensuring scalability and sustainability of health system strategies.
  • Foster and maintain strategic relationships with external partners, including industry consortia, diagnostic alliances, and integrated health networks, to enhance Karius’s market presence and collaborative growth opportunities.
  • Serve as a trusted liaison between Karius and strategic partners to ensure alignment on shared goals, joint initiatives, and long-term partnership success.
  • Represent Karius at executive-level meetings, national conferences, and health system forums to strengthen visibility and credibility.
  • Monitor healthcare trends, policy developments, and competitor activities to inform strategy and maintain market leadership.

Karius provides rapid, non-invasive infectious-disease diagnostics using the Karius Test, a liquid biopsy that detects over 1,000 pathogens from a single blood sample. The test analyzes microbial cell-free DNA circulating in the bloodstream, using advanced genomics and artificial intelligence to identify pathogens. It operates on real-time genomic data and a constantly updated reference database, enabling clinicians to diagnose infections without multiple invasive tests. Unlike traditional methods, Karius combines a broad pathogen panel with machine-learning analysis to deliver faster results and reduce unnecessary procedures. The company's goal is to help healthcare providers diagnose infections quickly, improve patient outcomes, and reduce healthcare costs by offering a faster, less invasive diagnostic option.

Company Size

201-500

Company Stage

Series C

Total Funding

$345M

Headquarters

Redwood City, California

Founded

2014

Get referred to Karius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BARDA awarded Karius a contract August 8, 2024 for agnostic pathogen detection.
  • Karius Test entered 2023 Duke-ISCVID endocarditis criteria, strengthening clinician acceptance.
  • Karius expanded access via Mayo Clinic Laboratories, speeding reporting within 24 hours of arrival.

What critics are saying

  • Blue Cross Blue Shield of Michigan upheld Karius denial December 16, 2025 as investigational.
  • Humana Kentucky Medicaid required prior authorization for Karius test on June 29, 2026.
  • FDA authorization lag keeps Karius dependent on LDT status until device clearance arrives.

What makes Karius unique

  • Karius Focus | BAL launched nationwide April 28, 2025 for immunocompromised pneumonia.
  • Karius earned FDA Breakthrough Device designation May 16, 2024 for lung infections.
  • Karius now reaches 600 hospitals through Mayo Clinic Laboratories collaboration April 23, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
Business Wire
May 16th, 2024
Karius Test® Receives Fda Breakthrough Device Designation To Aid In The Diagnosis Of Infectious Disease

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc., a leader in genomic diagnostics for infectious diseases, announced today that the Karius Test® has been granted designation as a Breakthrough Device from The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA), for use in the diagnosis and management of immunocompromised patients with suspected lung infections including lower respiratory infection and pneumonia. “The Karius Test is commercially available nationwide as a laboratory developed test. We are seeking FDA marketing authorization of the Karius Test for lung infections in immunocompromised patients because improved diagnostic tests are urgently needed for these patients,” stated Brad Perkins, M.D., Chief Medical Officer of Karius. “As noted in the American Thoracic Society (ATS) Workshop Report for Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria,1 lung infections have high morbidity and mortality in immunocompromised patients, which is why advances in technologies like metagenomic sequencing used for the Karius Test are vital in improving the diagnosis and treatment of these patients.”. The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these innovative medical devices

Forbes
May 8th, 2024
Innovationrx: Deepmind Unveils Its New Protein-Folding Ai Model Alphafold 3

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. A protein folding prediction in response to a small molecule generated by AlphaFold 3.Isomorphic LabsToday, Deepmind announced the launch of AlphaFold 3, the next generation of its AI software for structural biology, which has enabled thousands of researchers to predict the complicated chemical interactions involved with proteins. One major difference in the new iteration of the program: instead of just predicting protein folding, it predicts the interactions of other biological molecules as well including DNA, RNA and small molecules. The company published the accuracy of its predictions in the journal Nature.In addition to the new capabilities–which even includes the ability to make predictions based on epigenetic changes to DNA–the company has also launched AlphaFold Server, a web service that enables researchers to generate biochemical models without having to install the system itself from open source code, as was the case with previous iterations. Something else new is that AlphaFold now works with diffusion models – which are popularly known for being used by AI systems that generate images from text prompts – in place of some of its previous structural models.“The response to AlphaFold 2 was more than I could have ever imagined in terms of the kind of creativity and what the research community has done with it,” Deepmind research director John Jumper said at a press briefing

Citybiz
May 3rd, 2024
Karius Secures $100M in Series C

Karius, Inc., a genomic diagnostics company, has raised $100 million in a Series C funding round co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare. The funds will be used to expand the reach of the Karius Test®, which detects over 1,000 pathogens from a single blood sample, beyond 400 U.S. hospitals. The company also added three new board members, including Alex Morgan from Khosla Ventures, Joep Muijrers from Gilde Healthcare, and Andrew Booth from 5AM Ventures.

RamaOnHealthcare
May 2nd, 2024
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test

Karius secures $100M to expand non-invasive pathogen blood Test.

Business Wire
May 2nd, 2024
Karius Secures $100M for Genomic Diagnostics Expansion

Karius, Inc. has raised $100M in Series C funding, co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from Seventure Partners and others. The funds will expand the reach of the Karius Test®, a genomic diagnostic test for infectious diseases, beyond 400 U.S. hospitals. The investment also supports research into microbial cell-free DNA technology. Additionally, Karius announced three new board members.